Johanna Mariegaard1, Jonathan Wenstrup2,3,4, Kevin Zi Ming Lim3,5, Pernille Envold Bidstrup3, Annika von Heymann6, Christoffer Johansen6, Gitte Moos Knudsen1,5, Ian Law7, Lena Specht2, Dea Siggaard Stenbæk8. 1. Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, DK-2100, Copenhagen, Denmark. 2. Department of Oncology, Copenhagen University Hospital Rigshospitalet, DK-2100, Copenhagen, Denmark. 3. Psychological Aspects of Cancer, Survivorship Unit, Danish Cancer Society Research Center, DK-2100, Copenhagen, Denmark. 4. Department of Neurology, Bispebjerg-Frederiksberg Hospital, DK-2400, Copenhagen, Denmark. 5. Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100, Copenhagen, Denmark. 6. CASTLE Cancer Late Effects Research Unit, Department of Oncology, Copenhagen University Hospital Rigshospitalet, DK-2100, Copenhagen, Denmark. 7. Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen University Hospital Rigshospitalet, DK-2100, Copenhagen, Denmark. 8. Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, DK-2100, Copenhagen, Denmark. dea@nru.dk.
Abstract
PURPOSE: This study sought to investigate the prevalence of self-reported cognitive impairment and its relation to illness and treatment characteristics and mental health in Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL) survivors as cancer-related cognitive impairment has not been extensively studied in lymphoma survivors. METHODS: One hundred fifteen HL and DLBCL survivors (mean age = 40.3 years, mean months since completed treatment = 29.6) completed questionnaires on executive function and mental health. We examined the prevalence of executive impairment and compared illness and treatment characteristics and mental health across survivors reporting impaired and non-impaired executive functioning using chi-square, Cochran-Armitage, and Mann-Whitney U tests. RESULTS: We found that 39% reported executive impairment. Survivors reporting impaired executive functioning reported worse mental health (ps < .001) than survivors reporting non-impaired executive functioning. A larger proportion of the impaired group had received a high chemo dose compared to the non-impaired group although this result fell short of significance after adjustment for multiple comparisons (p = .017). CONCLUSIONS: Self-reported cognitive impairment is prevalent in HL and DLBCL survivors and is associated with worse mental health and possibly high chemo dose. Future studies should investigate objective impairment and the possible dose-response relationship between chemo dose and cognitive impairment in lymphoma survivors.
PURPOSE: This study sought to investigate the prevalence of self-reported cognitive impairment and its relation to illness and treatment characteristics and mental health in Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL) survivors as cancer-related cognitive impairment has not been extensively studied in lymphoma survivors. METHODS: One hundred fifteen HL and DLBCL survivors (mean age = 40.3 years, mean months since completed treatment = 29.6) completed questionnaires on executive function and mental health. We examined the prevalence of executive impairment and compared illness and treatment characteristics and mental health across survivors reporting impaired and non-impaired executive functioning using chi-square, Cochran-Armitage, and Mann-Whitney U tests. RESULTS: We found that 39% reported executive impairment. Survivors reporting impaired executive functioning reported worse mental health (ps < .001) than survivors reporting non-impaired executive functioning. A larger proportion of the impaired group had received a high chemo dose compared to the non-impaired group although this result fell short of significance after adjustment for multiple comparisons (p = .017). CONCLUSIONS: Self-reported cognitive impairment is prevalent in HL and DLBCL survivors and is associated with worse mental health and possibly high chemo dose. Future studies should investigate objective impairment and the possible dose-response relationship between chemo dose and cognitive impairment in lymphoma survivors.
Entities:
Keywords:
Cancer-related cognitive impairment; Diffuse large B cell lymphoma; Hodgkin lymphoma; Mental health; Self-reported cognitive function
Authors: Matthew J Ehrhardt; Daniel A Mulrooney; Chenghong Li; Malek J Baassiri; Kari Bjornard; John T Sandlund; Tara M Brinkman; I-Chan Huang; Deo Kumar Srivastava; Kirsten K Ness; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Cancer Date: 2017-09-15 Impact factor: 6.860
Authors: Ferenc Magyari; István Virga; Zsófia Simon; Zsófia Miltényi; Anna Illés; Karolina Kósa; Tibor Ivánka; Roland Berecz; Anikó Égerházi; Árpád Illés Journal: Support Care Cancer Date: 2022-03-11 Impact factor: 3.359